Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix natural daylight versus conventional photodynamic therapy for actinic keratosis
NL-OMON38765Phase 3Active, not recruiting
- Sponsor
- Galderma
- Start
- Sep 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of methyl aminolevulinate in actinic keratosis (AK) (3 arms), sponsored by Galderma. Started Sep 2013; status: active, not recruiting.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NL-OMON38765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38765.